Molecular and Cellular Biochemistry

, Volume 433, Issue 1–2, pp 113–123 | Cite as

Sestrin 2 attenuates neonatal rat cardiomyocyte hypertrophy induced by phenylephrine via inhibiting ERK1/2

Article
First Online:
Received:
Accepted:

Abstract

Cardiac hypertrophy is an adaptive response triggered by many physiological and pathological conditions and will lead to heart failure eventually. Sestrin 2, which is a stress-responsive protein, was reported to protect heart from ischemia reperfusion injury. However, the role of Sestrin 2 in cardiac hypertrophy remains unknown. In our present study, we aimed to explore the effects of Sestrin 2 on cardiomyocyte hypertrophy. We found that knockdown of Sestrin 2 protein aggravated cardiomyocyte hypertrophy induced by phenylephrine (PE), featured by increased hypertrophic marker ANP and cell surface area. During this process, ERK1/2 cascade was further activated, while p38, JNK1/2, and mTOR signaling pathways were not affected by downregulation of Sestrin 2. Moreover, overexpression of Sestrin 2 protein protected cardiomyocytes from PE-induced hypertrophy and ERK1/2 cascade was suppressed correspondingly. Importantly, pharmacological inhibition of ERK1/2 eliminated the exacerbated hypertrophic phenotype due to Sestrin 2 protein knockdown. In conclusion, we discovered that Sestrin 2 protected against cardiomyocyte hypertrophy induced by PE via inhibiting ERK1/2 signaling.

Keywords

Cardiomyocyte hypertrophy Sestrin 2 MAPK signaling pathway ERK1/2 Phenylephrine 

Abbreviations

PE

Phenylephrine

Hi 95

Hypoxia-inducible gene 95

MAPK

Mitogen-activated protein kinase

ERK1/2

Extracellular signal-regulated protein kinase

JNK1/2

c-Jun N-terminal protein kinase

mTOR

Mammalian target of rapamycin

mTORC1

mTOR complex 1

mTORC2

mTOR complex 2

This is a preview of subscription content, log in to check access.

Notes

Acknowledgements

This work is supported by the National Natural Science Foundation of China (Nos. 81200173, 81370338, 81470511 and 81570354), Guangdong Natural Science Foundation (Nos. S2013020012578 and 2015A030313111), the Ph.D. Programs Foundation of Ministry of Education of China (No. 20120171110074), and Guangdong Scientific Program Foundation (No. 2012B031800300).

Compliance with ethical standards

Conflict of interest

None declared.

Ethical approval

Our ethical approval number is “[2014]A-176” (approved by ethical committee of Sun Yat-sen University). All of the experimental protocols complied with the guide for the care and use of laboratory animals published by the Animal Care and Use Committees of the Sun Yat-Sen University and guide for the care and use of laboratory animals published by the US National Institutes of Health.

References

  1. 1.
    Pillai VB, Samant S, Sundaresan NR, Raghuraman H, Kim G, Bonner MY, Arbiser JL, Walker DI, Jones DP, Gius D, Gupta MP (2015) Honokiol blocks and reverses cardiac hypertrophy in mice by activating mitochondrial Sirt 3. Nat Commun 6:6656. doi: 10.1038/ncomms7656 CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Lee JH, Budanov AV, Karin M (2013) Sestrins orchestrate cellular metabolism to attenuate aging. Cell Metab 18:792–801. doi: 10.1016/j.cmet.2013.08.018 CrossRefPubMedGoogle Scholar
  3. 3.
    Rhee SG, Bae SH (2015) The antioxidant function of Sestrins is mediated by promotion of autophagic degradation of Keap1 and Nrf2 activation and by inhibition of mTORC1. Free Radic Biol Med 88(Part B):205–211. doi: 10.1016/j.freeradbiomed.2015.06.007 CrossRefPubMedGoogle Scholar
  4. 4.
    Peng M, Yin N, Li MO (2014) Sestrins function as guanine nucleotide dissociation inhibitors for Rag GTPases to control mTORC1 signaling. Cell 159:122–133. doi: 10.1016/j.cell.2014.08.038 CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Budanov AV, Karin M (2008) P53 target genes Sestrin 1 and Sestrin 2 connect genotoxic stress and mTOR signaling. Cell 134:451–460. doi: 10.1016/j.cell.2008.06.028 CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Saxton RA, Knockenhauer KE, Wolfson RL, Chantranupong L, Pacold ME, Wang T, Schwartz TU, Sabatini DM (2016) Structural basis for leucine sensing by the Sestrin2-mTORC1 pathway. Science 351:53–58. doi: 10.1126/science.aad2087 CrossRefPubMedGoogle Scholar
  7. 7.
    Yang Y, Cuevas S, Yang S, Villar VA, Escano C, Asico L, Yu P, Jiang X, Weinman EJ, Armando I, Jose PA (2014) Sestrin 2 decreases renal oxidative stress, lowers blood pressure, and mediates dopamine D2 receptor-induced inhibition of reactive oxygen species production. Hypertension 64:825–832. doi: 10.1161/HYPERTENSIONAHA.114.03840 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Kim H, An S, Ro SH, Teixeira F, Park GJ, Kim C, Cho CS, Kim JS Jakob U, Lee JH, Cho US (2015) Janus-faced Sestrin2 controls ROS and mTOR signalling through two separate functional domains. Nat Commun 6:10025. doi: 10.1038/ncomms10025 CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Budanov AV, Sablina AA, Feinstein E, Koonin EV, Chumakov PM (2004) Regeneration of peroxiredoxins by p53-regulated Sestrins, homologs of bacterial AphD. Science 304:596–600. doi: 10.1126/science.1095569 CrossRefPubMedGoogle Scholar
  10. 10.
    Bae SH, Sung SH, Oh SY, Lim JM, Lee SK, Park YN, Lee HE, Kang D, Rhee SG (2013) Sestrins activate Nrf2 by promoting p62-dependent autophagic degradation of Keap1 and prevent oxidative liver damage. Cell Metab 17:73–84. doi: 10.1016/j.cmet.2012.12.002 CrossRefPubMedGoogle Scholar
  11. 11.
    Kallenborn-Gerhardt W, Lu R, Syhr KM, Heidler J, von Melchner H, Geisslinger G, Bangsow T, Schmidtko A (2013) Antioxidant activity of Sestrin 2 controls neuropathic pain after peripheral nerve injury. Antioxid Redox Signal 19:2013–2023. doi: 10.1089/ars.2012.4958 CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Parmigiani A, Nourbakhsh A, Ding B, Wang W, Kim YC, Akopiants K, Guan KL, Karin M, Budanov AV (2014) Sestrins inhibit mTORC1 kinase activation through the GATOR complex. Cell Rep 9:1281–1291. doi: 10.1016/j.celrep.2014.10.019 CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Hou YS, Guan JJ, Xu HD, Wu F, Sheng R, Qin ZH (2015) Sestrin2 protects dopaminergic cells against rotenone toxicity through AMPK-dependent autophagy activation. Mol Cell Biol 35:2740–2751. doi: 10.1128/MCB.00285-15 CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Morrison A, Chen L, Wang J, Zhang M, Yang H, Ma Y, Budanov A, Lee JH, Karin M, Li J (2015) Sestrin 2 promotes LKB1-mediated AMPK activation in the ischemic heart. FASEB J 29:408–417. doi: 10.1096/fj.14-258814 CrossRefPubMedGoogle Scholar
  15. 15.
    Zeng YC, Chi F, Xing R, Zeng J, Gao S, Chen JJ, Wang HM, Duan QY, Sun YN, Niu N, Tang MY, Wu R (2016) Sestrin2 protects the myocardium against radiation-induced damage. Radiat Environ Biophys 55:195–202. doi: 10.1007/s00411-016-0643-8 CrossRefPubMedGoogle Scholar
  16. 16.
    Chang L, Karin M (2001) Mammalian MAP kinase signaling cascades. Nature 410:37–40. doi: 10.1038/35065000 CrossRefPubMedGoogle Scholar
  17. 17.
    Javadov S, Jang S, Agostini B (2014) Crosstalk between mitogen-activated protein kinases and mitochondria in cardiac diseases: therapeutic perspectives. Pharmacol Ther 144:202–225. doi: 10.1016/j.pharmthera CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Lu J, Bian ZY, Zhang R, Zhang Y, Liu C, Yan L, Zhang SM, Jiang DS, Wei X, Zhu XH, Chen M, Wang AB, Chen Y, Yang Q, Liu PP, Li H (2013) Interferon regulatory factor 3 is a negative regulator of pathological cardiac hypertrophy. Basic Res Cardiol 108:326. doi: 10.1007/s00395-012-0326-9 CrossRefPubMedGoogle Scholar
  19. 19.
    Muslin AJ (2008) MAPK signaling in cardiovascular health and disease: molecular mechanisms and therapeutic targets. Clin Sci 115:203–218. doi: 10.1042/CS20070430 CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Barry SP, Davidson SM, Townsend PA (2008) Molecular regulation of cardiac hypertrophy. Int J Biochem Cell Biol 40:2023–2039. doi: 10.1016/j.biocel.2008.02.020 CrossRefPubMedGoogle Scholar
  21. 21.
    Glennon PE, Kaddoura S, Sale EM, Sale JG, Fuller SJ, Sugden PH (1996) Depletion of mitogen-activated protein kinase using an antisense oligodeoxynucleotide approach downregulates the phenylephrine-induced hypertrophic response in rat cardiac myocytes. Circ Res 78:954–961. doi: 10.1161/01.RES.78.6.954 CrossRefPubMedGoogle Scholar
  22. 22.
    Bueno OF, De Windt LJ, Tymitz KM, Witt SA, Kimball TR, Klevitsky R, Hewett TE, Jones SP, Lefer DJ, Peng CF, Kitsis RN, Molkentin JD (2000) The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J 19:6341–6350. doi: 10.1093/emboj/19.23.6341 CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Yue TL, Gu JL, Wang C, Reith AD, Lee JC, Mirabile RC, Kreutz R, Wang Y, Maleeff B, Parsons AA, Ohlstein EH (2000) Extracellular signal-regulated kinase plays an essential role in hypertrophic agonists, endothelin-1 and phenylephrine-induced cardiomyocyte hypertrophy. J Biol Chem 275:37895–37901. doi: 10.1074/jbc.M007037200 CrossRefPubMedGoogle Scholar
  24. 24.
    Liang Q, Molkentin JD (2003) Redefining roles of p38 and JNK signaling in cardiac hypertrophy: dichotomy between cultured myocytes and animal models. J Mol Cell Cardiol 35:1385–1394. doi: 10.1016/j.yjmcc.2003.10.001 CrossRefPubMedGoogle Scholar
  25. 25.
    Volkers M, Toko H, Doroudgar S, Din S, Quijada P, Joyo AY, Ornrlas L, Joyo E, Thyerauf DJ, Konstandin MH, Gude N, Glembotski CC, Sussman MA (2013) Pathological hypertrophy amelioration by PRAS40-mediated inhibition of mTORC1. Proc Natl Acad Sci USA 110:12661–12666. doi: 10.1073/pnas.1301455110 CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Wang RH, He JP, Su ML, Luo J, Xu M, Du XD, Chen HZ, Wang WJ, Wang Y, Zhang N, Zhao BX, Zhao WX, Shan ZG, Han J, Chang C, Wu Q (2013) The orphan receptor TR3 participates in angiotensin II-induced cardiac hypertrophy by controlling mTOR signaling. EMBO Mol Med 5:137–148. doi: 10.1002/emmm.201201369 CrossRefPubMedGoogle Scholar
  27. 27.
    Malhowski AJ, Hira H, Bashiruddin S, Warburton R, Goto J, Robert B, Kwiatkowski DJ, Finalay GA (2011) Smooth muscle protein-22-mediated deletion of Tsc1 results in cardiac hypertrophy that is mTORC1-mediated and reversed by rapamycin. Hum Mol Genet 20:1290–1305. doi: 10.1093/hmg/ddq570 CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Pettazzoni P, Viale A, Shah P, Carugo A, Ying H, Wang H, Genovese G, Seth S, Minelli R, Green T, Huang-Hobbs E, Corti D, Sanchez N, Nezi L, Marchesini M, Kapoor A, Yao W, Francesco ME, Petrocchi A, Deem AK, Scott K, Colla S, Mills GB, Fleming JB, Heffernan TP, Jones P, Toniatti C, DePinho RA, Draetta GF (2011) Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer. Cancer Res 75:1091–1101. doi: 10.1158/0008-5472.CAN-14-1854 CrossRefGoogle Scholar
  29. 29.
    Turke AB, Song Y, Costa C, Cook R, Arteaga CL, Asara JM, Engelman JA (2012) MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. Cancer Res 72:3228–3237. doi: 10.1158/0008-5472.CAN-11-3747 CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC, Papa A, Nardella C, Cantley LC, Baselga J, Pandolfi PP (2008) Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Investig 118:3065–3074. doi: 10.1172/JCI34739 PubMedPubMedCentralGoogle Scholar
  31. 31.
    Melemedjian OK, Khoutorsky A, Sorge RE, Yan J, Asiedu MN, Valdez A, Ghosh S, Dussor G, Mogil JS, Sonenberg N, Price TJ (2013) mTORC1 inhibition induces pain via IRS-1-dependent feedback activation of ERK. Pain 154:1080–1091. doi: 10.1016/j.pain.2013.03.021 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  1. 1.Department of Cardiology, Heart CenterThe First Affiliated Hospital of Sun Yat-Sen UniversityGuangzhouChina
  2. 2.Key Laboratory on Assisted CirculationMinistry of HealthGuangzhouChina

Personalised recommendations